Diurnal Group Plc Get the rhythm

Hardman & Co ReportDiurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates – Infacort® and Chronocort® – in Phase III trials targeted at rare diseases with unmet medical need with which it aims to build a long-term ‘Adrenal Franchise’. The cortisol replacement market is for conditions that need life-long treatments, with a potential value of $3.5bn. Despite this, the market is characterised by few competitors, and Diurnal will target a network of specialist endocrinology centres in Europe and US by itself. Upcoming newsflow on trials and regulatory filings will draw attention to the stock.

 
► Strategy: Diurnal’s strategic goal is to create a valuable ‘Adrenal Franchise’ that can treat patients with chronic cortisol deficiency diseases. Once Infacort and Chronocort are established in Europe and the US, the long-term vision is to expand the product offering to other conditions linked to the endocrine system.

► Launch timetable: Infacort will be filed with the EMA in 4Q 2016, allowing a launch in 1Q 2018, with a US Phase III trial programme anticipated to be agreed with the FDA. Chronocort is in Phase III trials in Europe with the expectation of a launch in 2019; the US launch is expected to follow in 2021.

► Market opportunity: Diurnal will initially target the orphan conditions of congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI) which require life-long replacement of cortisol. Based on competitive pricing, Diurnal will be targeting addressable markets of ca.$3.5bn.

► Risks: As with all drug development companies, there is a risk that products will fail in clinical trials. However, Diurnal is much lower risk given that its products are formulation variants of well-established drugs. The main risk to forecasts will be management’s ability to obtain the desired in-market prices for its drugs.

► Investment summary: A risk-adjusted DCF model of its two leading products suggests that Diurnal Group Plc should be trading at 399p per share, with an EV of £208m. This is supported by relative valuation analysis compared to peer group of similar stage development companies in the field of endocrinology, with Corcept (CORT.OQ) being a good example of valuation potential when sales are achieved.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Diurnal Group: All set for three pivotal trials

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader.

    Hardman & Co

    Diurnal Group: And then there were three

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group: Closely watching the regulators

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group Flow of regulatory approvals

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group … and more to come (news flow)

    Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building

    Hardman & Co

    Diurnal Group Plc Successful DITEST Phase I trial outcome

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful

    Hardman & Co

    Diurnal Group Approaching a number of near-term milestones

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Plc Clarity for Chronocort regulatory pathway

    Diurnal Group Plc (LON: DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of

    Hardman & Co

    Diurnal Group Chronocort – seeking regulatory advice

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Unexpected Phase III trial outcome

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Alkindi®: On route to Europe

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building